Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 13/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.37 |
| ▸ | CTSB | P07858 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | CTSV | O60911 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1012642 | 0.78 | MEN1 (0.34) | HRH3 | |
| SCHEMBL1013096 | 0.76 | CYP2C19 (0.44) | TACR1TMEM97CARM1PRMT6SIGMAR1 | |
| SCHEMBL2231171 | 0.75 | HRH3 (0.31) | HRH3 | |
| SCHEMBL2231802 | 0.75 | MAPT (0.41) | — | |
| SCHEMBL2234744 | 0.73 | NR1I2 (0.33) | SIGMAR1HTR2AHTR7 | |
| SCHEMBL1012697 | 0.72 | ALDH1A1 (0.34) | HRH3 | |
| SCHEMBL1010853 | 0.68 | ALDH1A1 (0.32) | — | |
| SCHEMBL2233257 | 0.68 | ALDH1A1 (0.32) | — | |
| SCHEMBL2230316 | 0.67 | — | — | |
| SCHEMBL6422792 | 0.66 | CYP2C19 (0.36) | TACR1CYP2C19CTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372844-B1 | HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR | CALIFORNIA INST OF TECHN (US) | 2011-01-05 | — | — | EP | claimed |
| US-6838489-B2 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | CYMETECH, LLC (US) | 2005-01-04 | — | — | US | claimed |
| US-20030144437-A1 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | STERLING JA, L.C. | 2003-07-31 | — | — | US | claimed |
| US-20030083445-A1 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | STERLING JA, L.C. | 2003-05-01 | — | — | US | claimed |
| US-20120241250-A1 | Aerial Work Platforms and Aerial Work Platform Assemblies Comprised of Polymerized Cycloolefin Monomers | EAKIN GEORGE R (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120241250-A1 | Aerial Work Platforms and Aerial Work Platform Assemblies Comprised of Polymerized Cycloolefin Monomers | EAKIN GEORGE R (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120241250-A1 | Aerial Work Platforms and Aerial Work Platform Assemblies Comprised of Polymerized Cycloolefin Monomers | EAKIN GEORGE R (US) | 2012-09-27 | — | — | US | disclosed |
| EP-1372844-B1 | HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR | CALIFORNIA INST OF TECHN (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-1372844-A4 | HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR | CALIFORNIA INST OF TECHN (US) | 2005-10-12 | — | — | EP | disclosed |
| US-6838489-B2 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | CYMETECH, LLC (US) | 2005-01-04 | — | — | US | disclosed |
| EP-1372844-A1 | HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR | California Institute of Technology (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2003097562-A2 | HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030144437-A1 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | STERLING JA, L.C. | 2003-07-31 | — | — | US | disclosed |
| US-20030083445-A1 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | STERLING JA, L.C. | 2003-05-01 | — | — | US | disclosed |
| WO-2002076613-A1 | HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144437-A1 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | NQO1, NIT2, ALOX5 | TACR1 3890/4885TMEM97 1842/4885CARM1 3656/4885 |
| US-20030083445-A1 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | NQO1, NIT2, ALOX5 | TACR1 3890/4885TMEM97 1842/4885CARM1 3656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.